CD37 and B-cell chronic lymphocytic leukemia: Another chimeric Fc-engineered anti-CD37 molecule with improved ADCC–BI 836826, successfully targets CLL cells [81], including a chemo-resistant side population, and has demonstrated increased efficacy when combined with PI3K inhibitor idelalisib [50].